TITLE

Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care

AUTHOR(S)
Farahani, Pendar; Levine, Mitchell; Gaebel, Kathryn; LeLorier, Jacques; Perreault, Sylvie; Gillis, Jane; Soon, Judith
PUB. DATE
April 2007
SOURCE
Clinical & Investigative Medicine;Apr2007, Vol. 30 Issue 2, pE63
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Lipid-lowering therapeutics, particularly HMG Co-A reductase inhibitors, can be beneficial in primary and secondary cardiovascular prevention. The Canadian population frequently uses these medications but the manner in which they are used in community-based practice is unknown. Objectives: To assess the patient characteristics associated with lipid lowering drug use in community-based clinical practice across four geographic regions in Canada. To assess amongst lipid-lowering drugs users the proportion of patients that would meet accepted dyslipidemia management guidelines. To assess the community-based effectiveness of anti-hyperlipidemic drugs. Methods: Patients filling a prescription for any antihyperlipidemia therapy in selected pharmacies in Ontario (ON), Quebec (PQ), British Columbia (BC) and Nova Scotia (NS). All eligible patients were interviewed over the telephone. Physicians who were providing healthcare to the participating patients were requested to provide information from the patient's medical record. Results: The mean patient age was > 60 yr in all four provinces. There were some differences amongst the four provinces pertaining to patient characteristics, prescription patterns and therapeutic indicators, but not to outcomes. Antihyperlipidemia therapy was associated with a 1.81 mmol/L decrease in LDL-Cholesterol (P < 0.001); however only 73% of patients achieved target LDL-Cholesterol concentrations. A lag time of 1.96 yr (P < 0.0001) was observed from the diagnosis of dyslipidemia until the drug treatment was initiated. Patients had an average of 2.8 cardiovascular (CV) risk factors and 86% of patients had at two or more CV risk factors. Thirty-nine percent (95% CI, 36% - 42%) of the patients were being treated for secondary prevention. Thirteen percent (11% - 16%) of patients who were being treated for primary prevention had diabetes. Metabolic syndrome was observed in 32% (29% - 35%) of patients. Conclusion: Almost all patients fulfilled guideline requirements for the use of anti-hyperlipidemic therapy. Although the use of pharmacotherapy was associated with a lowering of LDL cholesterol more aggressive management is required to attain target LDL cholesterol concentrations.
ACCESSION #
25385122

 

Related Articles

  • `Statins' given during acute MI or unstable coronary disease may reduce short-, long-term mortality.  // Geriatrics;May2000, Vol. 55 Issue 5, p69 

    Discusses how lipid-lowering therapy at the time of acute myocardial infarction can reduce mortality. How HMG-CoA reductase inhibitors or statins work; Other benefits of a statin given immediately to patients hospitalized for episodes of non-ST elevation acute coronary syndromes.

  • New Advances in Lipid-Modifying Therapies for Reducing Cardiovascular Risk. Bruckert, Eric // Cardiology;2002, Vol. 97 Issue 2, p59 

    Over the last 30 years, several epidemiological and prospective studies have identified a number of risk factors for the development of cardiovascular disease. Lipid abnormalities are central among these risk factors, and their correction has been a major target for the medical community. The...

  • HMG-CoA Reductase Inhibitors Inhibit Inducible Nitric Oxide Synthase Gene Expression in Macrophages. Kuo-Chin Huang; Ching-Wen Chen; Jui-Ching Chen; Wan-Wan Lin // Journal of Biomedical Science;Jul/Aug2003, Vol. 10 Issue 4, p396 

    The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, statins, are potent inhibitors of cholesterol synthesis and have wide therapeutic use in cardiovascular diseases. Recent evidence, however, suggests that the beneficial effects of statins may extend beyond their action on...

  • Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Toth, Peter P. // Vascular Health & Risk Management;May2016, Vol. 12, p171 

    Approximately 25% of US adults are estimated to have hypertriglyceridemia (triglyceride [TG] level ≥150 mg/dL [≥1.7 mmol/L]). Elevated TG levels are associated with increased cardiovascular disease (CVD) risk, and severe hypertriglyceridemia (TG levels ≥500 mg/dL [≥5.6...

  • Statins reduce cardiovascular risk. Mayor, Susan // BMJ: British Medical Journal (International Edition);7/6/2002, Vol. 325 Issue 7354, p5 

    States that treatment of patients at high risk of cardiovascular events with HMG-CoA reductase inhibitor simvastatin reduced the risk of myocardial infarction, stroke, and revascularization by about one third. Details of the heart protection study, led by Jane Armitage, consultant in public...

  • Drug Costs Associated with Non-Adherence to Cholesterol Management Guidelines for Primary Prevention of Cardiovascular Disease in an Elderly Population: The Rotterdam Study. Gumbs, Pearl D.; Verschuren, W. M. Monique; Mantel-Teeuwisse, Aukje K.; de Wit, Ardine G.; Hofman, Albert; Trienekens, Paul H.; Stricker, Bruno H. Ch.; de Boer, Antonius; Klungel, Olaf H. // Drugs & Aging;2006, Vol. 23 Issue 9, p733 

    BACKGROUND: In The Netherlands, costs of HMG-CoA reductase inhibitor (statin) use have recently increased sharply compared with costs of other drugs. However, several studies have established both undertreatment and non-guidelines-indicated treatment with statins, suggesting a suboptimal use of...

  • Safety of Simvastatin and Goal Attainment for Low-Density Lipoprotein Cholesterol in Sultan Qaboos University Hospital. Al-Siyabi, Khalid; Farhan, Hatem; Al-Rasadi, Khalid; Al-Salhi, Amaal; Al-Hinai, Ali T.; Al-Zakwani, Ibrahim // Oman Medical Journal;Oct2010, Vol. 25 Issue 4, p264 

    Objectives: Despite the scientific evidence of reducing cardiac events with HMG Co-A reductase inhibitors (statins) therapy in both primary and secondary preventions, these therapies continue to be underutilized in patients receiving convictional care. Simvastatin, a HMG Co-A inhibitor agent, is...

  • Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors. Smaldone, Costantino; Brugaletta, Salvatore; Pazzano, Vincenzo; Liuzzo, Giovanna // Cardiovascular & Hematological Agents in Medicinal Chemistry;2009, Vol. 7 Issue 4, p279 

    Statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA are best known for their lipid-lowering effects but they also possess immunomodulatory properties that are, at least in part, independent of changes in serum cholesterol. Some recent clinical trials (eg. PROVE-IT) have shown that statins...

  • Lipid Lowering Effects of Hydroalcoholic Extract of Anethum graveolens L. and Dill Tablet in High Cholesterol Fed Hamsters. Abbasi Oshaghi, Ebrahim; Khodadadi, Iraj; Saidijam, Massoud; Yadegarazari, Reza; Shabab, Nooshin; Tavilani, Heidar; Goodarzi, Mohamad Taghi // Cholesterol;12/28/2015, p1 

    Objective. This study was aimed to determine the effect of Anethum graveolens extract and Anethum graveolens (dill) tablet on lipid profile, liver enzymes, and gene expression and enzymatic activity of HMG-CoA reductase in high cholesterol fed hamsters. Materials and Methods. Golden Syrian male...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics